Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.96 USD | +3.66% | +3.94% | -18.85% |
Business Summary
Number of employees: 330
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Instruments
43.6
%
| 39 | 51.6 % | 42 | 43.6 % | +8.96% |
Service and Other
30.2
%
| 17 | 23.0 % | 29 | 30.2 % | +69.81% |
Consumables
25.0
%
| 18 | 24.6 % | 24 | 25.0 % | +31.31% |
Standalone Software
1.2
%
| 1 | 0.8 % | 1 | 1.2 % | +85.69% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
North America
60.3
%
| 42 | 56.2 % | 58 | 60.3 % | +38.62% |
EMEA
22.6
%
| 18 | 23.7 % | 22 | 22.6 % | +22.76% |
APAC
17.1
%
| 15 | 20.1 % | 17 | 17.1 % | +9.93% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Brian McKelligon
CEO | Chief Executive Officer | 55 | 01/17/01 |
Johnny Ek
DFI | Director of Finance/CFO | 48 | 20/23/20 |
Pascal Bamford
CTO | Chief Tech/Sci/R&D Officer | - | 26/21/26 |
Frederic Pla
COO | Chief Operating Officer | 65 | 31/21/31 |
Peter J. Miller
CTO | Chief Tech/Sci/R&D Officer | - | 01/18/01 |
Priyam Shah
IRC | Investor Relations Contact | - | - |
General Counsel | 53 | 28/23/28 | |
Gavin Gordon
PRN | Corporate Officer/Principal | - | 01/20/01 |
- | - | ||
Corporate Officer/Principal | 49 | 01/20/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Shepler
CHM | Chairman | 67 | 01/15/01 |
Myla Lai-Goldman
BRD | Director/Board Member | 66 | 16/21/16 |
Director/Board Member | 67 | 01/19/01 | |
Matthew Winkler
BRD | Director/Board Member | 71 | 01/17/01 |
Thomas Raffin
BRD | Director/Board Member | 77 | 01/15/01 |
Brian McKelligon
CEO | Chief Executive Officer | 55 | 01/17/01 |
Scott Mendel
BRD | Director/Board Member | 57 | 11/21/11 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 49,140,731 | 25,340,022 ( 51.57 %) | 0 | 51.57 % |
Company contact information
Sector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.85% | 196M | |
+8.33% | 219B | |
+6.72% | 183B | |
+10.18% | 132B | |
+24.91% | 106B | |
-1.86% | 62.09B | |
+10.56% | 50.8B | |
+4.81% | 50.88B | |
-0.24% | 40.64B | |
+1.22% | 35.71B |
- Stock Market
- Equities
- AKYA Stock
- Company Akoya Biosciences, Inc.